InteliSpark client, Zymtronix, is awarded $2.9 million from the National Institutes of Health via the Small Business Innovation Research program. Researchers will have the opportunity to accelerate their work in the production of complex human milk oligosaccharides (HMOs) based on their innovative immobilized enzyme technology.
HMOs, the third largest component found in human breast milk, lead to stronger immune systems in breast-fed babies compared to formula-fed babies. HMOs feed good bacteria in the gut and are also absorbed into the baby’s blood stream to support the developing immune system. Broader research is also investigating the possibility of prebiotic, anti-inflammatory, anti-cancer, antimicrobial, and even antiviral properties in HMOs.
According to the Centers of Disease Control, 60% of mothers reported not breastfeeding for as long as they intended to and had to rely on formula. Factors contributing to stopping breastfeeding early include, but are not limited to, issues with lactation and latching, concerns about infant nutrition and weight, unsupportive work policies or lack of maternal leave. For some mothers, breastfeeding is not an option even from the time of birth of their child. Researchers have attempted to introduce HMOs into infant formula, but the biggest challenge is accessibility and affordability of complex synthetic glycans.
As a recipient of this competitive award, Zymtronix has the potential to advance their work in the production of HMOs to improve infant formula. The company’s unique technology in enzyme immobilization significantly improves HMO production efficiency while also establishes substantial cost savings.